Quad Capital Management Advisors LLC purchased a new position in shares of C R Bard Inc (NYSE:BCR) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 76,400 shares of the medical instruments supplier’s stock, valued at approximately $24,367,000. C R Bard comprises about 10.0% of Quad Capital Management Advisors LLC’s investment portfolio, making the stock its 2nd largest holding. Quad Capital Management Advisors LLC owned approximately 0.10% of C R Bard as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Amalgamated Bank raised its holdings in C R Bard by 8.5% in the 4th quarter. Amalgamated Bank now owns 9,484 shares of the medical instruments supplier’s stock valued at $3,141,000 after acquiring an additional 740 shares in the last quarter. NuWave Investment Management LLC acquired a new position in C R Bard in the 4th quarter valued at $546,000. MUFG Securities EMEA plc acquired a new position in C R Bard in the 4th quarter valued at $49,686,000. Charter Research & Investment Group Inc. acquired a new position in C R Bard in the 4th quarter valued at $497,000. Finally, GABELLI & Co INVESTMENT ADVISERS INC. raised its holdings in C R Bard by 72.4% in the 4th quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 194,629 shares of the medical instruments supplier’s stock valued at $64,541,000 after acquiring an additional 81,744 shares in the last quarter. 79.11% of the stock is owned by hedge funds and other institutional investors.
Shares of BCR opened at $331.24 on Friday. C R Bard Inc has a 52-week low of $222.42 and a 52-week high of $337.73. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.57.
Separately, Zacks Investment Research raised C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price objective for the company in a report on Tuesday, December 26th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $320.83.
ILLEGAL ACTIVITY NOTICE: “Quad Capital Management Advisors LLC Purchases New Position in C R Bard Inc (NYSE:BCR)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/quad-capital-management-advisors-llc-buys-shares-of-76400-c-r-bard-inc-bcr.html.
About C R Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.